<DOC>
	<DOCNO>NCT01448174</DOCNO>
	<brief_summary>Hyperlipidemia atherosclerosis lead cardiovascular disease indirect cause increase death rate general population . This association still evident specific subpopulation , like patient advanced chronic kidney disease ( CKD ) , especially hemodialysis ( HD ) patient , due high prevalence lipid disturbance atherosclerosis compare general population . Cardiovascular event CKD patient frequently associate traditional risk factor , include diabetes , male sex , hypertension , dyslipidemia advance age . However , factor fail fully account increase risk cardiovascular event CKD . The effort make identify new risk factor contribute development atherosclerosis participate cause cardiovascular death . In 2003 , identify peptide designate salusin-alpha salusin-beta . Development atherosclerosis may suppress salusin-alpha . Salusin-alpha may lipid lower effect , similar statin . The purpose study investigate whether 1 ) salusin-alpha associate lipid metabolism HD patient ( without metabolic syndrome type 2 diabetes mellitus ) , similarly like healthy obese subject ; 2 ) treatment atorvastatin effect associate change plasma salusin-alpha concentration , - whether dependent direct influence atorvastatin salusin-alpha associate decrease serum lipid level ; 3 ) salusin-alpha may predict mortality HD patient .</brief_summary>
	<brief_title>Salusin-alpha - New Factor Pathogenesis Lipid Abnormalities Hemodialysis Patients</brief_title>
	<detailed_description>Purpose I , step 1 . To investigate whether plasma salusin-alpha associate lipid lipid-related abnormality hemodialysis ( HD ) patient , plasma salusin-alpha concentration , expression receptor CD36 macrophage , serum lipid parameter , anthropometric laboratory index nutrition biomarkers inflammation cross-sectionally analyze . In chronic kidney disease ( CKD ) patient close association atherosclerosis ( A ) , malnutrition ( M ) inflammation ( I ) , know MIA syndrome , interaction parameter obviously present take account . In addition , homeostasis model assessment insulin resistance ( HOMA-IR ) apply insulin resistance metabolic abnormality occur advanced CKD , metabolic syndrome show 50 % HD patient diabetic mellitus ( DM ) , cause CKD approximately 40 % case . Results correlation association show HD patient compare healthy control obese person normal renal function evaluation salusin-alpha relationship different metabolic condition , may exert uniform influence . Study population : HD patient ( n = 200 ) Obese person ( n = 50 ) Controls ( n = 60 ) Data collection : Medical history ( special attention demographic - age , gender , cause CKD , renal replacement therapy vintage , change body weight , habit data require inclusion exclusion criterion . Physical examination ( special attention skin abnormality relate lipid disturbance blood pressure ) . Anthropometric index : - directly measure : height , body weight , hip waist circumference , midarm circumference ( MAC ) , triceps skin fold thickness ( TSF ) - calculate estimate : hip waist ratio ( WHiR ) , height waist ratio ( WHeR ) , body mass index ( BMI ) , HD patient - dry body weight ( DBW ) Laboratory parameter - Apolipoprotein A1 ( APOA1 ) - Apolipoprotein B ( APO B ) - Cholesterol - total - Cholesterol HDL - Cholesterol LDL directly measure - CD36 - Free fatty acid ( FDA ) - High sensitivity C-reactive protein ( hsCRP ) - HOMA-IR - Interleukin 6 ( IL-6 ) - L-carnitine - Lipase - Lipoprotein ( ) - Salusin-alpha - Triglycerides - Basic serum biochemistry Purpose I , step 2 . HD patient suffer type 2DM metabolic syndrome ( MeS ) risk severe lipid abnormality remain one . Data collect Step 1 helpful diagnosis MeS examine HD patient . The investigator expect also control find person abnormal serum lipid profile . Differences inside group may influence plasma salusin-alpha level examine association . Thereby , follow group analyze separately compare : For HD patient : - group MeS type 2 DM - group MeS - group type 2 DM - group without MeS without DM For control : - group without detect serum lipid abnormality - group detect serum lipid abnormality Validation correlations/associations find cross-sectional study do prospective study ( Purpose II ) final analysis ( Purpose III ) . Purpose II . The treatment atorvastatin lower serum LDL cholesterol HD patient . Using statin study , investigator observe dynamic change serum LDL cholesterol HD patient know plasma salusin-alpha concentration atorvastatin medication . With repeated salusin-alpha measurement continue atorvastatin treatment investigator follow concomitantly occur ( occur ) change plasma salusin-alpha concentration , relate atorvastatin directly LDL cholesterol lower effect . To elucidate aspect , investigator plan examine hyperlipidemic HD patient treat prescribed diet increase physical activity well obese person ( take lipid lower medication ) weight lower therapy , usually decrease lipidemia . Results person may give answer whether decrease lipidemia without pharmaceutical medication lead ( may also lead ) change plasma salusin-alpha concentration . The prospective study plan two group person : HD patient , participate Step 1 ( n = 200 ) , Obese person , participate Step 1 ( n = 50 ) . Purpose III . Annual mortality rate HD patient 10 - 15 % . LDL cholesterol total cholesterol predictor mortality end-stage renal disease patient . If salusin-alpha associate lipid abnormality , reasonable check whether peptide may predictor mortality HD patient . To investigate aspect investigator plan perform analysis HD patient outcome two year first salusin-alpha determination check whether association plasma salusin-alpha concentration death cardiovascular event cause death .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>For HD patient : HD vintage least 3 month sign consent participation study For obese person : BMI &gt; 30 kg/m2 eGFR &gt; 60 ml/min/1.73 m2 BSA interest weight loss accord weight loss diet protocol ( WLDP ) sign consent participation study For control ( healthy volunteer ) : declare health , comfort substantial change medical interview physical examination medication sign consent participation study For HD patient : active thyroid gland disease and/or thyreotropic medication treatment corticosteroid , immunosuppressant hormones treatment statin fibrates 6 week study commencement diagnosis genetic lipid abnormality neoplastic disease acute coronary syndrome and/or cerebral stroke 6 month study commencement surgery 3 month study commencement plasma activity ALT and/or AST exceed 3 time upper laboratory normal limit non compensate diabetes mellitus For obese person : know history moderate severe cardiovascular disease , stroke transient ischemic attack uncontrolled hypertension severe dyslipidemia ( triglyceride &gt; 500 mg/dl , total cholesterol &gt; 350 mg/dl ) take lipidlowering agent recruitment 6 week serious chronic disease require active treatment ( example glucocorticoid , antineoplastic agent , psychoactive agent , bronchodilator regular basis , insulin oral hypoglycemic drug ) woman childbearing potential use effective form hormonal birth control , pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>salusin-alpha</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>CD36</keyword>
	<keyword>Hemodialysis</keyword>
</DOC>